Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CABOTEM: Cabozantinib and Temozolomide in Advanced NENs
NCT04893785Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2021
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib in lung neuroendocrine neoplasm (L-NEN), gastroenteropancreatic neuroendocrine tumor (GEP-NET), sponsored by National Cancer Institute. Started Jun 2021; status: recruiting.
02
Drugs
cabozantinib
03
Conditions
lung neuroendocrine neoplasm (L-NEN)gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT04893785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04893785.